In conclusion, we investigated somatic mosaic PPM1D mutations in patients with various cancers, including breast and ovarian cancers and found that all four patients bearing the truncating mutations had a history of cisplatin-based chemotherapy. This evidence concerns the gene PPM1D and ovarian carcinoma.